Overview

Continuous vs. Intermittent Infusion Vancomycin

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.
Phase:
Phase 4
Details
Lead Sponsor:
Alexander Flannery
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Vancomycin